Passaro, Carmela (2013) PARP inhibition as new approach to increase the oncolytic activity of the adenoviral mutant dl922-947 against Anaplastic Thyroid Carcinoma. [Tesi di dottorato]

[img]
Anteprima
Testo
Passaro_Carmela_25.pdf

Download (7MB) | Anteprima
[error in script] [error in script]
Tipologia del documento: Tesi di dottorato
Lingua: English
Titolo: PARP inhibition as new approach to increase the oncolytic activity of the adenoviral mutant dl922-947 against Anaplastic Thyroid Carcinoma
Autori:
AutoreEmail
Passaro, Carmelacarmela.passaro@virgilio.it
Data: 2 Aprile 2013
Numero di pagine: 152
Istituzione: Università degli Studi di Napoli Federico II
Dipartimento: Medicina Molecolare e Biotecnologie Mediche
Scuola di dottorato: Medicina molecolare
Dottorato: Oncologia ed endocrinologia molecolare
Ciclo di dottorato: 25
Coordinatore del Corso di dottorato:
nomeemail
Santoro, Massimomasantor@unina.it
Tutor:
nomeemail
Portella, Giuseppeportella@unina.it
Data: 2 Aprile 2013
Numero di pagine: 152
Parole chiave: Oncolytic adenoviruses; PARP inhibitors
Settori scientifico-disciplinari del MIUR: Area 06 - Scienze mediche > MED/05 - Patologia clinica
Area 06 - Scienze mediche > MED/06 - Oncologia medica
Area 06 - Scienze mediche > MED/13 - Endocrinologia
Aree tematiche (7° programma Quadro): SALUTE e TUTELA DEL CONSUMATORE > Biotecnologie, strumenti e tecnologie generiche per la salute umana
Depositato il: 11 Apr 2013 14:07
Ultima modifica: 31 Dic 2016 02:00
URI: http://www.fedoa.unina.it/id/eprint/9413

Abstract

Anaplastic Thyroid Carcinoma (ATC) is one of the most aggressive tumor characterized by an average survival time of 3-6 months after diagnosis. Multimodality therapy, which includes surgical debulking, external radiation therapy and chemotherapy, has failed to show any improvements in survival. Therefore, novel therapies with different mechanisms of action are required. Oncolytic viruses (OVs) represent a novel therapeutic tool for the treatment of aggressive tumors. OVs as single agents have demonstrated limited efficacy in a clinical setting, thus highlighting the need of novel combinatorial therapies (i.e. OVs plus a rationally selected drug) with a potential great impact on clinical use. In this study, we showed that the oncolytic adenovirus dl922-947 induces massive S-phase entry in ATC cell lines, followed by an extensive DNA damage, quantified by γH2AX staining. Moreover, we demonstrated that dl922-947 triggered a DNA damage response, characterized by the activation of the checkpoint kinases ATM and Chk1, and at the same time impaired the ability of the DNA repair, by affecting MRN complex protein levels. The virus-induced single-strand DNA breaks (SSBs) activate the Poly-ADP-Ribose Polymerase (PARP) to signal SSBs to the enzymatic machinery involved in their repair. Here, we demonstrate that the pharmacological inhibition of PARP increases dl922-947 cytotoxicity against Anaplastic Thyroid Carcinoma both in vitro and in vivo. We also show that PARP inhibitor AZD2281 synergizes with dl922-947 increasing viral replication and accelerating cell death pathways. Furthermore, we showed that the virus as single treatment induced an apoptotic-like cell death, as indicated by the presence of Caspase 3 activation, PARP cleavage, Annexin V positivity and Cytochrome C release from mitochondria, although lacking the morphological features of apoptosis. In this regard we also proved that dl922-947 acts on the pathway involved in membrane blebbing by inhibiting Myosin Light Chain 2 (MLC2) phosphorylation. Using a pan caspase inhibitor, both caspase-dependent and -independent cell death pathways are found activated upon dl922-947 infection. Our data clearly suggest that the combination of the oncolytic adenovirus dl922-947 with PARP inhibitor could represent a novel and effective therapeutic approach for the treatment of Anaplastic Thyroid Carcinoma.

Actions (login required)

Modifica documento Modifica documento